• 1
    Kenemans P. Menopause, HRT and menopausal symptoms. J Epidemiol Biostat 1999; 4: 1416.
  • 2
    Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 32133.
  • 3
    Hulley S, Furberg C, Barrett-Connor E. Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II): noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288: 5866.
  • 4
    Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 9424.
  • 5
    Manson JE, Martin KA. Clinical practice: postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345: 3440.
  • 6
    IARC. Monographs on the evaluation of carcinogenic risks to human. Hormonal contraception and post-menopausal hormonal therapy. vol. 72. Lyon: IARC, 1999.
  • 7
    Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 14605.
  • 8
    Gallus S, Negri E, Chatenoud L, Bosetti C, Franceschi S, La Vecchia C. Post-menopausal hormonal therapy and gallbladder cancer risk. Int J Cancer 2002; 99: 7623.
  • 9
    Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F, Franceschi S. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 32933.
  • 10
    Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 57482.
  • 11
    Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999; 4: 191210.
  • 12
    Chatenoud L, Tavani A, La Vecchia C, Jacobs DR Jr, Negri E, Levi F, Franceschi S. Whole grain food intake and cancer risk. Int J Cancer 1998; 77: 248.
  • 13
    Breslow NE, Day NE. Statistical methods in cancer research. The analysis of case-control studies. vol 1. Lyon: IARC, Sci Publ, Vol. 32; 1980.
  • 14
    Franceschi S, La Vecchia C. Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev 1998; 7: 42738.
  • 15
    Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomark Prev 1998; 7: 6539.
  • 16
    Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991; 115: 4556.
  • 17
    McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 1985; 75: 18591.
  • 18
    Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992; 12: 132730.
  • 19
    Meggouh F, Lointier P, Pezet D, Saez S. Status of sex steroid hormone receptors in large bowel cancer. Cancer 1991; 67: 196470.
  • 20
    Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson EN, Baylin SB. Methylation of the oestrogen receptor CpG islands links ageing and neoplasia in human colon. Nat Genet 1994; 7: 53640.
  • 21
    Goodman-Gruen D, Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab 1996; 81: 426871.
  • 22
    Campagnoli C, Biglia N, Cantamessa C, Lesca L, Lotano MR, Sismondi P. Insulin-like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values. Gynecol Endocrinol 1998; 12: 25966.
  • 23
    Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab 1999; 84: 228690.
  • 24
    Kam GY, Leung KC, Baxter RC, Ho KK. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000; 85: 191822.
  • 25
    Baghdiguian S, Verrier B, Gerard C, Fantini J. Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth. Cancer Lett 1992; 62: 2333.
  • 26
    Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999; 51 (Suppl 3): 3441
  • 27
    McCarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity. Med Hypotheses 2001; 56: 2136.
  • 28
    La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001; 39: 97115.
  • 29
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 32732.
  • 30
    Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83: 18206.
  • 31
    Goodman MT, Moriwaki H, Vaeth M, Akiba S, Hayabuchi H, Mabuchi K. Prospective cohort study of risk factors for primary liver cancer in Hiroshima and Nagasaki, Japan. Epidemiology 1995; 6: 3641.
  • 32
    Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993; 67: 6357.
  • 33
    Shimizu I, Yasuda M, Mizobuchi Y, Ma YR, Liu F, Shiba M, Horie T, Ito S. Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut 1998; 42: 1129.
  • 34
    Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001; 54: 13844.
  • 35
    Fraumeni JF Jr, Devesa SS, McLaughlin JK, Standford JL. Biliary tract cancers. In: SchotenfeldD, FraumeniJFJr, eds. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 794805.
  • 36
    Chow WH, McLaughlin JK, Menck HR, Mack TM. Risk factors for extrahepatic bile duct cancers: Los Angeles County, California (USA). Cancer Causes Control 1994; 5: 26772.
  • 37
    Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, Jain M, Przewozniak K, Baghurst P, Moerman CJ, Simard A, Howe GR, McMichael AJ, Hsieh CC, Walker AM. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89: 11328.
  • 38
    La Vecchia C, Negri E, D'Avanzo B, Parazzini F, Gentile A, Franceschi S. Oral contraceptives and non-contraceptive oestrogens in the risk of gallstone disease requiring surgery. J Epidemiol Comm Health 1992; 46: 2346.
  • 39
    Uhler ML, Marks JW, Judd HL. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 2000; 7: 1627.
  • 40
    Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II). JAMA 2002; 288: 5866.
  • 41
    Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 30413.
  • 42
    Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996; 275: 3705.
  • 43
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 11317.
  • 44
    Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000; 2: CD000402.
  • 45
    Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98107.
  • 46
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 104759.
  • 47
    Silverman DT, Morrison AS, Devesa SS. Bladder cancer. In: SchotenfeldD, FraumeniJFJr, eds. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press, 1996. 115679.
  • 48
    Negri E, La Vecchia C. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 2001; 10: 714.
  • 49
    Cantor KP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992; 3: 5762.
  • 50
    Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. Prev Med 2002; 35: 11420.
  • 51
    Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497504.
  • 52
    Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 33441.
  • 53
    Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002; 94: 61729.
  • 54
    Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers: evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000; 74: 35764.
  • 55
    Parazzini F, La Vecchia C, Negri E, Bianchi C, Fedele L. Determinants of estrogen replacement therapy use in northern Italy. Rev Epidem Sante Publ 1993; 41: 538.
  • 56
    Banks E, Beral V, Cameron R, Hogg A, Langley N, Barnes I, Bull D, Elliman J, Harris CL. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 2001; 6: 35763.
  • 57
    Kelly JP, Rosenberg L, Kaufman DW, Shapiro S. Reliability of personal interview data in a hospital-based case-control study. Am J Epidemiol 1990; 131: 7990.
  • 58
    Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 2001; 54: 9026.